A new approach for analysing patient compliance

Article

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications.

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications, according to a report published in the August issue of the American Journal of Ophthalmology.

Paul P. Lee and colleagues from the Eye Center at Duke University, North Carolina, USA conducted a retrospective study of prescription refill patterns. Patients with prescriptions for 2.5 ml bottles of latanoprost, travoprost and bimatoprost were identified from a retail pharmacy database and were followed-up for 12 months. Three separate analyses defined gaps in therapy as spans in excess of 45, 60 or 120 days without a refill for the same medication. Patients were categorised by the number of gaps in therapy and the cumulative length of gaps. A Kaplan-Meier analysis was conducted using a 120-day allowable refill period.

The results showed that, for refill periods of 45, 60 and 120 days, 10.6%, 28.6% and 77.5% of patients, respectively, had no gaps in therapy and that 32.6%, 53.4% and 86.5%, respectively, had 30 days or fewer off therapy in a 12-month period. According to the 45-day threshold analysis, 50.7% of subjects had three or more gaps versus 18.5% in the 60-day analysis and none in the 120-day analysis. The Kaplain-Meier curve demonstrated that 88.6% and 76.1% of subjects were persistent for 120 days and one year, respectively.

According to the researchers, it would appear that a gap analysis approach to analysing patient compliance is more accurate than using Kaplan-Meier survival curves.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.